When patients face life-threatening conditions or rare diseases with no approved treatment options in their country, accessing investigational or unapproved medications becomes critical. Two primary regulatory pathways enable this access: named patient programs and compassionate use programs. While these terms are often used interchangeably, they have distinct regulatory frameworks, eligibility criteria, and implementation processes.

This comprehensive guide explains the differences between named patient program and compassionate use, helping patients, healthcare providers, and pharmaceutical professionals understand when and how to utilize each pathway for accessing named patient medicines and compassionate use drugs globally.

What is a Named Patient Program?

A named patient program (NPP) is a regulatory mechanism that allows individual patients to access medications that are not approved or commercially available in their country. Named patient supply is provided on a named patient basis, meaning each case is evaluated individually with specific patient identification and medical justification.

Key Characteristics of Named Patient Programs:

• Individual Patient Focus: Each request is for a specifically identified patient with documented medical need
• Physician-Driven: Requires prescription and medical justification from a licensed healthcare provider
• Regulatory Approval: Must obtain approval from national health authorities (EMA, MHRA, TGA, MFDS, NMPA, etc.)
• Post-Market Access: Often used for medications approved in other countries but not yet registered locally
• Commercial Framework: Typically involves payment by patient, insurance, or healthcare system

When Named Patient Programs Are Used:

Named patient programs are commonly utilized in the following scenarios:

• Accessing rare disease treatments not approved in the patient's country
• Obtaining medications approved by FDA, EMA, or other international regulatory authorities but pending local approval
• Emergency access to life-saving treatments for critical medical conditions
• Sourcing orphan drugs for ultra-rare genetic disorders
• Accessing specialty medications with limited global distribution

What is Compassionate Use?

Compassionate use, also known as expanded access, is a regulatory pathway that allows patients with serious or immediately life-threatening diseases to access investigational drugs that have not yet received regulatory approval when no comparable or satisfactory alternative therapy options exist.

Key Characteristics of Compassionate Use:

• Pre-Approval Access: Enables access to drugs still in clinical development (Phase II/III trials)
• No Alternatives Required: Patient must have exhausted all approved treatment options
• Serious Condition Criteria: Reserved for life-threatening or severely debilitating conditions
• Regulatory Oversight: Governed by strict FDA, EMA, or local health authority guidelines
• Manufacturer Cooperation: Requires pharmaceutical company consent to provide compassionate use drugs

Compassionate Use Policy Frameworks:

Compassionate use programs operate under different regulatory frameworks globally:

• United States (FDA): Expanded Access Program with individual patient, intermediate-size population, and treatment IND pathways
• European Union (EMA): Compassionate use programs managed at national level with EMA guidance
• United Kingdom (MHRA): Early Access to Medicines Scheme (EAMS) and compassionate use provisions
• Australia (TGA): Special Access Scheme (SAS) for unapproved therapeutic goods
• Canada (Health Canada): Special Access Programme (SAP) for drugs not authorized for sale

Named Patient Program vs Compassionate Use: Side-by-Side Comparison

Aspect	Named Patient Program	Compassionate Use
Primary Purpose	Access to approved medications not available locally	Access to investigational drugs before regulatory approval
Drug Status	Usually approved in at least one country	Still in clinical development (not yet approved anywhere)
Patient Eligibility	Individual patients with medical need on named patient basis	Patients with serious/life-threatening conditions, no alternatives
Regulatory Pathway	Import authorization, special use permits	Expanded access, compassionate use authorization
Geographic Terminology	Common in Europe, Asia, Middle East	Common in United States, Canada
Cost Structure	Patient/insurance typically pays commercial price	Often provided free or reduced cost by manufacturer
Approval Timeline	Days to weeks (faster for emergencies)	Weeks to months (depends on complexity)
Documentation Required	Physician prescription, medical justification, import permits	Detailed clinical justification, IRB approval (in some cases)
Manufacturer Role	May not require direct manufacturer involvement	Requires manufacturer consent and drug provision
Data Collection	Minimal monitoring requirements	Often requires safety data reporting

Understanding Regional Regulatory Frameworks

Named Patient Programs by Region:

European Union - Named Patient Programs

In the European Union, named patient programs are managed at the national level by individual member state health authorities. The European Medicines Agency (EMA) provides guidance, but each country implements its own named patient supply framework. Common requirements include physician prescription, medical justification demonstrating unmet need, and import authorization from national regulatory authorities.

United Kingdom - Named Patient Supply

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) regulates named patient supply through the "specials" framework. Healthcare providers can request unlicensed medicines on a named patient basis when no suitable licensed alternative exists. The prescriber takes full responsibility for the treatment decision.

Asia-Pacific - Named Patient Programs

Countries like South Korea (MFDS), China (NMPA), Japan (PMDA), and Australia (TGA) have established named patient access pathways. In India, named patient program India initiatives operate under the Central Drugs Standard Control Organization (CDSCO) framework, allowing import of unapproved medications for individual patients with proper documentation.

Compassionate Use Programs by Region:

United States - FDA Expanded Access

The FDA's expanded access program allows patients with serious diseases to access investigational drugs outside clinical trials. Three pathways exist: individual patient access (emergency use), intermediate-size patient population access, and treatment IND/treatment protocol for widespread use. The compassionate use policy requires that the patient has a serious condition, no comparable alternatives exist, potential benefits justify risks, and expanded access won't interfere with ongoing clinical trials.

European Union - Compassionate Use Framework

The EMA provides guidance on compassionate use programs, but implementation occurs at national level. Each EU member state defines eligibility criteria, approval processes, and monitoring requirements for compassionate use drugs. Common criteria include life-threatening diseases, no authorized treatment alternatives, and inability to participate in clinical trials.

Australia - Special Access Scheme

Australia's Therapeutic Goods Administration (TGA) operates the Special Access Scheme (SAS), which serves as both a named patient program and compassionate use pathway. SAS Category A covers immediately life-threatening conditions, Category B covers serious conditions, and Category C covers experimental treatments in clinical trials.

Eligibility Criteria and Documentation Requirements

Named Patient Program Eligibility:

Compassionate Use Eligibility:

Documentation Required for Both Pathways:

• Medical Documentation: Complete medical records, diagnosis, treatment history
• Physician Justification: Detailed rationale explaining medical necessity
• Patient Consent: Informed consent acknowledging investigational nature or unapproved status
• Regulatory Applications: Country-specific forms for import authorization or compassionate use approval
• Quality Certificates: Pharmaceutical quality documentation for named patient medicines
• Treatment Protocol: Proposed dosing, monitoring plan, and safety reporting procedures

Compassionate Use and Clinical Trials: Understanding the Connection

While compassionate use and compassionate use clinical trials both involve accessing investigational treatments, they serve different purposes within the drug development ecosystem.

Compassionate Use Outside Clinical Trials:

Standard compassionate use programs provide access to investigational drugs for individual patients who cannot participate in clinical trials due to geographic limitations, ineligibility criteria, trial closure, or urgent medical need. These programs operate independently of clinical trial protocols, though they may require basic safety data collection.

Compassionate Use Clinical Trial Programs:

Some pharmaceutical companies establish formal compassionate use clinical trials (also called open-label extension studies or expanded access protocols) that combine compassionate access with structured data collection. These programs serve dual purposes:

• Providing treatment access to patients who completed pivotal trials or need ongoing therapy
• Gathering additional safety and efficacy data in larger, more diverse patient populations
• Enabling access while awaiting regulatory approval decisions
• Supporting post-marketing surveillance and real-world evidence generation

How GNH India Supports Named Patient Programs and Compassionate Use

As a global pharmaceutical supplier with over two decades of experience, GNH India Pharmaceuticals plays a critical role in facilitating access to named patient medicines and supporting compassionate use programs worldwide. Our expertise in international pharmaceutical supply, regulatory compliance, and patient access programs enables healthcare providers to obtain critical treatments for their patients through both named patient and compassionate use pathways.

GNH India's Named Patient Program Support:

• Global Sourcing Network: Access to named patient medicines from 180+ countries, including medications approved by FDA, EMA, MHRA, TGA, and other international regulatory authorities
• Named Patient Program India Expertise: Comprehensive support for named patient India initiatives, including CDSCO compliance and import licensing
• Regulatory Documentation: Complete assistance with country-specific import applications, physician justification letters, and quality certificates
• Named Patient Basis Processing: Individual case management ensuring each patient receives personalized attention and rapid response
• Cold Chain Logistics: GDP-compliant temperature-controlled supply chain for biologics and temperature-sensitive named patient medicines

Supporting Compassionate Use Drug Access:

• Manufacturer Coordination: Liaison with pharmaceutical manufacturers operating compassionate drug programs to facilitate patient access
• Emergency Access: Expedited sourcing and delivery for compassionate use drugs in urgent, life-threatening situations
• Regulatory Guidance: Expert consultation on compassionate use policy requirements across different regulatory jurisdictions
• Documentation Support: Assistance with expanded access applications, IRB submissions, and compassionate use authorization requests
• International Distribution: Seamless cross-border logistics ensuring compassionate use drugs reach patients safely and rapidly

Why Healthcare Providers Choose GNH India:

• ✓ WHO-GSDP certified pharmaceutical supplier with proven quality assurance
• ✓ ISO 9001:2015 certified operations ensuring consistent service excellence
• ✓ Extensive experience with named patient supply across Europe, Asia-Pacific, Middle East, and Africa
• ✓ Comprehensive understanding of compassionate use policy frameworks in major regulatory jurisdictions
• ✓ 24/7 support for emergency patient access requirements
• ✓ Complete regulatory compliance with CDSCO, international export regulations, and destination country import requirements

Choosing the Right Pathway: Decision Framework

Selecting between a named patient program and compassionate use depends on several factors related to the medication, patient condition, and regulatory environment. This decision framework helps healthcare providers determine the appropriate access pathway:

Consider Named Patient Program When:

• Medication is already approved in at least one country (FDA, EMA, MHRA, TGA, etc.)
• Patient needs access to medication not yet approved locally but available commercially elsewhere
• Regulatory import authorization pathway exists in patient's country
• Payment mechanism available (insurance, patient, healthcare system)
• Faster approval timeline required (days to weeks rather than months)
• Physician can prescribe on named patient basis with medical justification

Consider Compassionate Use When:

• Drug is still investigational and not approved in any country
• Patient has life-threatening condition with no approved treatment alternatives
• Patient ineligible for or unable to access clinical trials
• Pharmaceutical manufacturer has established compassionate drug program
• Willing to comply with safety monitoring and data reporting requirements
• Patient and physician accept risks associated with investigational treatment

The Future of Named Patient Programs and Compassionate Use

The landscape of patient access to unapproved medications continues to evolve as regulatory authorities worldwide work to balance patient safety, drug development incentives, and urgent medical needs. Several trends are shaping the future of named patient programs and compassionate use:

Regulatory Harmonization:

International regulatory bodies are increasingly collaborating to streamline compassionate use policies and named patient supply frameworks. The International Council for Harmonisation (ICH) and WHO are working toward greater consistency in patient access pathways, potentially simplifying cross-border access to named patient medicines and compassionate use drugs.

Digital Health Integration:

Electronic submission systems, digital health records, and telemedicine platforms are making it easier for physicians to request named patient supply and compassionate use authorization. These technologies reduce administrative burden, accelerate approval timelines, and improve patient access to critical treatments.

Expanded Manufacturer Programs:

Pharmaceutical companies are increasingly establishing proactive compassionate drug programs and named patient supply channels as part of their global access strategies. This shift recognizes both ethical obligations to patients and potential benefits of real-world evidence generation before formal regulatory approval.

Emerging Market Access:

Countries in Asia-Pacific, Latin America, and Africa are developing or refining named patient program frameworks, expanding access to innovative treatments for patients in emerging markets. India's growing role in named patient program India initiatives and pharmaceutical exports positions companies like GNH India at the forefront of global patient access solutions.

Conclusion: Empowering Patient Access Through Multiple Pathways

Understanding the differences between named patient programs and compassionate use is essential for healthcare providers, patients, and pharmaceutical professionals navigating the complex landscape of access to unapproved medications. While these pathways serve similar goals—providing access to potentially life-saving treatments—they operate under distinct regulatory frameworks with different eligibility criteria, approval processes, and implementation requirements.

Key points to remember:

• Named patient programs provide access to medications approved elsewhere on a named patient basis through import authorization
• Compassionate use enables access to investigational drugs before regulatory approval for patients with serious conditions
• Both pathways require strong medical justification, regulatory approval, and careful patient selection
• Geographic terminology varies, with "named patient supply" common in Europe/Asia and "compassionate use" prevalent in the United States
• Professional pharmaceutical suppliers like GNH India facilitate both pathways through global sourcing, regulatory expertise, and compliant distribution

As a trusted pharmaceutical supplier with extensive experience in named patient program India operations and international compassionate use support, GNH India remains committed to bridging the gap between patients in need and life-saving medications worldwide. Our comprehensive regulatory knowledge, global sourcing network, and patient-focused approach ensure that healthcare providers can access critical treatments through the most appropriate pathway for each unique patient situation.

Whether you need named patient medicines for rare disease patients, support for compassionate use drug access in urgent cases, or guidance navigating international pharmaceutical supply regulations, GNH India's dedicated team is here to help ensure your patients receive the treatments they need, when they need them.